相似文献
1
Clinical progression of methicillin-resistant Staphylococcus aureus vertebral osteomyelitis associated with reduced susceptibility to daptomycin.
J Clin Microbiol. 2005 Oct;43(10):5384-7. doi: 10.1128/JCM.43.10.5384-5387.2005.
2
Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
J Clin Microbiol. 2006 Feb;44(2):595-7. doi: 10.1128/JCM.44.2.595-597.2006.
3
Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.
J Clin Microbiol. 2006 Feb;44(2):655-6. doi: 10.1128/JCM.44.2.655-656.2006.
4
Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
J Clin Microbiol. 2008 Mar;46(3):1132-6. doi: 10.1128/JCM.01844-07. Epub 2008 Jan 16.
5
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
6
Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis.
J Antimicrob Chemother. 2006 Feb;57(2):301-5. doi: 10.1093/jac/dki435. Epub 2005 Dec 16.
7
Daptomycin therapy for invasive Gram-positive bacterial infections in children.
Pediatr Infect Dis J. 2007 Dec;26(12):1128-32. doi: 10.1097/INF.0b013e31814523f8.
8
Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Clin Infect Dis. 2004 Apr 1;38(7):994-1000. doi: 10.1086/383472. Epub 2004 Mar 11.
9
The use of daptomycin for Staphylococcus aureus infections in critical care medicine.
Crit Care Clin. 2008 Apr;24(2):349-63, ix-x. doi: 10.1016/j.ccc.2007.12.010.
10
Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
Diagn Microbiol Infect Dis. 2008 Apr;60(4):437-40. doi: 10.1016/j.diagmicrobio.2007.11.002. Epub 2007 Dec 21.
引用本文的文献
1
Advances in Peptidomimetics for Next-Generation Therapeutics: Strategies, Modifications, and Applications.
Chem Rev. 2025 Aug 13;125(15):7099-7166. doi: 10.1021/acs.chemrev.4c00989. Epub 2025 Jul 23.
2
The Influence of Antibiotic Resistance on Innate Immune Responses to Infection.
Antibiotics (Basel). 2022 Apr 19;11(5):542. doi: 10.3390/antibiotics11050542.
3
Verification of a Novel Approach to Predicting Effects of Antibiotic Combinations: In Vitro Dynamic Model Study with Daptomycin and Gentamicin against .
Antibiotics (Basel). 2020 Aug 25;9(9):538. doi: 10.3390/antibiotics9090538.
4
Multidrug-Resistant Organisms: Considerations in Antibiotic Selection and Administration.
J Pediatr Intensive Care. 2015 Jun;4(2):87-96. doi: 10.1055/s-0035-1556751.
5
Staphylococcus aureus metabolic adaptations during the transition from a daptomycin susceptibility phenotype to a daptomycin nonsusceptibility phenotype.
Antimicrob Agents Chemother. 2015 Jul;59(7):4226-38. doi: 10.1128/AAC.00160-15. Epub 2015 May 11.
6
Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections.
Antimicrob Agents Chemother. 2015 Apr;59(4):1969-76. doi: 10.1128/AAC.04141-14. Epub 2015 Jan 20.
7
Additional routes to Staphylococcus aureus daptomycin resistance as revealed by comparative genome sequencing, transcriptional profiling, and phenotypic studies.
PLoS One. 2013;8(3):e58469. doi: 10.1371/journal.pone.0058469. Epub 2013 Mar 15.
8
Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.
Ann N Y Acad Sci. 2013 Jan;1277(1):139-58. doi: 10.1111/j.1749-6632.2012.06819.x. Epub 2012 Dec 5.
9
Daptomycin therapy for osteomyelitis: a retrospective study.
BMC Infect Dis. 2012 Jun 12;12:133. doi: 10.1186/1471-2334-12-133.
10
Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.
Antimicrob Agents Chemother. 2012 Feb;56(2):838-44. doi: 10.1128/AAC.05551-11. Epub 2011 Nov 28.
本文引用的文献
1
Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2005 Apr 1;40(7):1058-60. doi: 10.1086/428616. Epub 2005 Feb 17.
2
Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.
Clin Infect Dis. 2004 Apr 1;38(7):994-1000. doi: 10.1086/383472. Epub 2004 Mar 11.
3
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
4
Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms.
J Antimicrob Chemother. 2004 Apr;53(4):669-74. doi: 10.1093/jac/dkh143. Epub 2004 Feb 25.
5
Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci.
J Clin Microbiol. 2003 Oct;41(10):4740-4. doi: 10.1128/JCM.41.10.4740-4744.2003.
6
Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2003 May;47(5):1714-8. doi: 10.1128/AAC.47.5.1714-1718.2003.
7
Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests.
Diagn Microbiol Infect Dis. 2000 Sep;38(1):51-8. doi: 10.1016/s0732-8893(00)00164-4.
8
Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits.
Antimicrob Agents Chemother. 1989 May;33(5):689-92. doi: 10.1128/AAC.33.5.689.
9
Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia.
Antimicrob Agents Chemother. 1992 May;36(5):1109-14. doi: 10.1128/AAC.36.5.1109.
Zotero 插件